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ABSTRACT 
A temporary ileostomy may reduce symptoms of anastomotic leakage after rectal 
resection for cancer. However, the stoma itself is associated with morbidity and 
early closure may reduce these symptoms. The aim of this thesis, based on a 
multicentre randomized controlled trial (EASY trial), was to evaluate early closure 
(8-13 days) of a temporary ileostomy compared to late closure (>12 weeks), after 
rectal resection for cancer. Endpoints were complications, quality of life, 
healthcare costs and bowel function. The trial included 55 patients in the early 
closure group, and 57 patients in the late closure group. 
Paper I evaluated number of postoperative complications up to 12 months 
following rectal resection. We found significantly fewer complications in the early 
closure group. Severe complications were uncommon in both groups.  
Paper II included assessment of patient reported quality of life, by validated 
questionnaires at 3, 6 and 12 months. There were no significant differences 
between the two groups. 
Paper III comprised a cost analysis, comparing direct costs from a healthcare 
perspective. Early closure was found to be significantly less costly at evaluation 
12 months after surgery. 
Paper IV was a cross-sectional study performed at median 4 years after rectal 
resection, comparing patient reported bowel function. The late closure group 
reported more problems with urgency, compared with the early closure group. 
There was no difference in prevalence of low anterior resection syndrome. 
Overall, in selected patients without signs of postoperative complications, early 
closure of a temporary ileostomy after rectal resection for cancer was found to be 
safe and clinically advantageous in a randomized trial setting. 
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 SAMMANFATTNING PÅ SVENSKA 
 
Bakgrund 
I Sverige diagnosticeras ca 2000 personer årligen med ändtarmscancer, och tjock- 
och ändtarmscancer är den tredje vanligaste cancerformen i västvärlden. 
Behandlingen utgörs av enbart eller en kombination av strålning, cellgifter och 
kirurgi. Vid botande kirurgisk behandling opererar man bort tumören med 
marginal, vilket medför att man även tar med större delen av ändtarmen. Man 
skapar då en s.k. anastomos, en förbindelse mellan nedre delen av ändtarmen och 
tjocktarmen. Denna anastomos är känslig på grund av sitt utsatta läge nära 
bäckenbotten. Därför anlägger man enligt rutin (efter tidigare studiers resultat) en 
temporär stomi på tunntarmsnivå, för att skydda anastomosen från tarminnehåll. 
Stomin i sig orsakar dock ofta besvär med höga flöden från tarmen, risk för 
intorkning och njursvikt samt är orsaken till flertalet inläggningar. Man brukar ha 
kvar sin stomi i minst 12 veckor innan man opererar tillbaka tarmen och återställer 
tarmkontinuiteten (nedläggning av stomin).  
 
Syfte 
Syftet med studien var att undersöka möjligheterna och säkerheten till tidig 
nedläggning av stomin, dvs. redan inom 8-13 dagar efter operationen för tumören 
i ändtarmen. Detta gjordes genom en randomiserad studie (EASY studien) där 
patienter blev lottade mellan tidig (8-13 dagar) och sen (minst 12 veckor) 
nedläggning av stomin. Studien undersökte också livskvalitet och tarmfunktion 
hos patienterna samt jämförde direkta sjukvårdskostnader för respektive grupp.  
 
Metod 
Vuxna patienter som genomgick operation för ändtarmscancer, och där 
återhämtningen gick bra, utan tecken till komplikationer, bjöds in till att medverka 
i studien. Röntgenundersökning med kontrast gjordes av anastomosen och om 
det inte fanns några tecken till läckage, lottades sedan patienterna antingen till 
tidig nedläggning (interventionsgruppen) eller sen nedläggning (kontrollgruppen). 
Interventionsgruppen lade ner sin stomi inom 8-13 dagar efter 
ändtarmsoperationen, medan kontrollgruppen fick sin stomi nedlagd efter minst 
 12 veckor (rutinsjukvård). Patienterna följdes i 12 månader för studie I-III, och 
även vid ca 4 år (studie IV).  
 
Resultat 
Studie I undersökte antal komplikationer som patienterna drabbades av upp till 
12 månader efter ändtarmsoperationen. Vi fann att patienterna i den tidiga 
nedläggningsgruppen drabbades av färre komplikationer, men att allvarliga 
komplikationer, såsom reoperationer och organsvikt, var ovanliga i båda 
behandlingsgrupperna.  
Studie II undersökte patientrapporterad livskvalitet vid 3, 6 och 12 månader efter 
ändtarmsoperationen. Detta mättes med hjälp av enkäter som patienterna fick 
svara på vid respektive uppföljningstillfälle. Vi såg ingen skillnad mellan 
behandlingsgrupperna, och resultaten var jämförbara med tidigare studiers 
resultat. 
Studie III utgjorde en kostnadsanalys, där syftet var att jämföra direkta 
sjukvårdskostnader, vilka baserades på bland annat röntgenundersökningar, 
återbesök, återinläggningar och reoperationer. Resultaten visade att det var 
mindre kostsamt att lägga ner sin stomi tidigt, men också att det var hälften så 
vanligt att återinläggas på sjukhus under 12 månaders perioden efter 
ändtarmsoperationen, jämfört med sen nedläggning av stomin.   
I studie IV jämfördes tarmfunktion hos patienterna i respektive grupp, med hjälp 
av två formulär. Det ena formuläret mätte förekomst av s.k. lågt främre 
resektionssyndrom, ett tillstånd där tarmfunktionen är försämrad vilket ger 
uttryck i bland annat inkontinens, täta trängningar och ofullständig tarmtömning. 
Studien gjordes under hösten 2017, vilket innebar en median uppföljningstid på 
ca 4 år efter ändtarmsoperationen. Trängningar och brådska till toaletten var 
vanligare i den sena nedläggningsgruppen, men det fanns ingen skillnad i 
förekomsten av lågt främre resektionssyndrom, även om förekomsten var 
generellt hög i båda behandlingsgrupperna.   
 
Slutsats 
Sammanfattningsvis har den randomiserade studien påvisat att hos utvalda 
patienter, utan tecken till komplikationer efter operation för ändtarmscancer, är 
det säkert och kliniskt gynnsamt att lägga ner en temporär stomi tidigt i förloppet.    
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1 INTRODUCTION 
 
1.1 RECTAL CANCER 

Colorectal cancer is the third most common cancer disease in the western world. 
In Sweden the incidence is increasing (figure 1) and currently approximately 2000 
individuals are diagnosed with rectal cancer each year1, 2. Since the 1980s there has 
been a change in surgical treatment strategy, where the previous method of blunt 
dissection of the rectum has been replaced by following the anatomical planes, 
total mesorectal excision (TME)3. Together with the initiation of preoperative 
(chemo)radiotherapy, the local recurrence rates have decreased substantially and 
oncological outcome has improved4-6. This has rendered an increase in five-year 
relative survival for rectal cancer, which is now in general approximately 60%7-9. 
A study based on data from the Swedish colorectal cancer registry including 
patients who had undergone rectal resection for cancer (where approximately 
85% were with curative intent), reported a three year survival rate of 
approximately 75% and a 5-year local recurrence rate of 5%10.  
Evaluation of patients and treatment strategies (including neo-adjuvant 
chemo/radiotherapy, adjuvant chemotherapy and choice of surgical technique) 
are together with patients’ comorbidity and general condition, based on tumour-
specific characteristics. These include tumour node metastasis classification, 
height of tumour (distance from the anal verge), engagement of circumferential 
margin or mesorectal fascia and signs of extramural vascular invasion. The 
evidence for the different treatment options are of various levels and even though 
national guidelines exist, there is no international consensus for the treatment of 
rectal cancer and adherence to defined guidelines varies11, 12. 
 
 
Figure 1. Annual number of 
patients diagnosed with rectal 
cancer 1970-2016 in Sweden. 
Number of patients (y-axis) 
diagnosed each year (x-axis), where 
blue represents men and red women. 
Data and diagram presented with 
permission from the Swedish 
Cancer Society (available at 
www.cancercentrum.se) 
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1.2 SURGICAL TREATMENT STRATEGIES 
 
Low anterior resection  
Low anterior resection with total mesorectal excision (TME) has increasingly 
been regarded as the optimal surgical treatment for potentially curable carcinoma 
in the mid rectum3, 9, 13, 14. The principles of TME surgery include sharp dissection 
under direct vision in the embryological avascular planes between the visceral and 
parietal pelvic fascia, removing the rectum with intact mesorectum14. Even 
though the introduction of training programs and centralization of rectal cancer 
surgery has led to decreased mortality and morbidity, rectal cancer surgery is still 
associated with complications, where anastomotic leakage is one of the most 
feared15-17. 
 
 
 
 
 
Anastomotic leakage  
Anastomotic leakage in the colo-anal anastomosis is a complication with 
considerable consequences including mortality, delayed start of adjuvant 
chemotherapy, poor long-term outcome and decreased quality of life18, 19. Risk 
factors for anastomotic leakage are low tumour height, radiotherapy, male sex, 
smoking, obesity, immunosuppression and emergency resection17, 20, 21. The 
suspicion of an anastomotic leak may be obvious in a severely ill patient with 
Figure 2. Anatomy of the rectum in men and women respectively 
Rectum 
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peritonitis, but may also be asymptomatic. The diagnostic tools suggested to 
investigate the anastomosis in a stable, less ill patient are computed tomography 
(CT), preferable with rectal contrast, and in selected cases flexible endoscopy 
(sigmoidoscopy). However the sensitivity and specificity varies22, 23. The following 
definition of anastomotic leakage after anterior resection has been suggested: ‘a 
communication between the intra- and extraluminal compartments at the site of 
the anastomosis’. A grading system for severity has also been proposed with grade 
A: requiring no active therapeutic intervention, grade B: requiring active 
intervention (for example drainage) but manageable without re-laparotomy and 
grade C: requiring re-laparotomy24. Validation of the grading system in 746 
patients with sphincter preserving rectal cancer surgery with a primary 
anastomosis, revealed an overall leakage rate of 7.5% and that grade A patients 
had an uneventful postoperative course (asymptomatic). Patients with grade C 
leakage (thus requiring re-laparotomy) comprised more than half of the leakage 
cases25.  
One approach to decrease the risk of anastomotic leakage is to optimize the 
conditions for the anastomosis to heal, by diverting the bowel contents away from 
the anastomosis. This can be done by the formation of a temporary ileostomy 
during the operation for the rectal tumour and requires a second operation for 
stoma closure.  
 
Temporary ileostomy  
In an attempt to reduce number of anastomotic leakages and their consequences, 
a Swedish randomized controlled trial investigated the role of the formation of a 
defunctioning stoma in conjunction with anterior resection for cancer. Results 
revealed significantly fewer symptomatic anastomotic leakages (10.3% vs 28%) 
and less need for urgent reoperation (8.6% vs 25.4%) in the group with a diverting 
stoma26. Other studies have reached similar conclusions27-29, which have resulted 
in the routine use of a diverting stoma (often a temporary loop ileostomy) in 
patients undergoing TME surgery for mid rectal tumours, in many countries 
including Sweden.  
Regardless the benefits of less symptoms if anastomotic leakage would occur, 
there is considerable morbidity related to the temporary ileostomy. Various 
complications occur with rates up to 50%30-32, including readmissions, 
dehydration and chronic renal failure33, 34. The patients are also in need of a second 
operation (closure) with the inherent risk of postoperative complications, such as 
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wound infection and small bowel obstruction34. Most patients with a temporary 
ileostomy will keep their stoma for at least three months, but it is not unusual that 
the stoma is left in place much longer, and for a few patients it becomes 
permanent35. Because of this associated morbidity, studies have suggested a more 
selective use of diverting stoma36. There are however difficulties in identifying 
which patients who would benefit from a stoma, even though many risk factors 
for anastomotic leakage are known20. A nomogram has been suggested to 
preoperatively be able to predict the risk of anastomotic leakage after colon 
resections37. However, when tested on patients who had undergone rectal 
resection, the sensitivity was low38.  
Previous studies have shown that patients with a stoma may suffer from impaired 
health related quality of life (HRQoL)39 where especially complications such as 
stoma leakage, parastomal skin irritation, retraction and prolapse of the stoma 
have significant impact on the patient's daily life40.  
 
 
 
Timing of stoma closure 
Rather than omitting the stoma in preoperatively selected patients, with the risk 
of considerable consequences if an anastomotic leak occurs, early closure has 
been considered a potential option41, 42. The timing of stoma closure has 
previously been investigated in a few prospective studies that mainly focused on 
morbidity and mortality related to early closure of the stoma41, 42. These studies 
did not demonstrate any significant effect related to early closure, although wound 
Figure 3. Formation of a loop ileostomy 
(below) of the distal part of the ileum, through 
the abdominal wall (left) in the lower right 
quadrant. Copyright Diedrick 
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infection at the stoma sight seemed to be more common. In other studies, 
investigating the possibility of an early closure, the results have been promising, 
but were inconclusive43, 44. A recent meta-analysis, including results from three 
randomized controlled trials (RCTs) (one of which was the EASY trial), one 
prospective and two retrospective studies, proposed early closure for selected 
patients with the absence of anastomotic leakage and uneventful postoperative 
outcomes45. 
 
 
1.3 QUALITY OF LIFE AND FUNCTIONAL 
OUTCOME 
 
According to the World Health Organization (WHO) the main ambition of 
cancer diagnosis and treatment programs are to cure or considerably prolong the 
life of patients and to ensure the best possible quality of life (QoL) for cancer 
survivors46. Improved multidisciplinary management has led to cure or prolonged 
survival of rectal cancer patients and the effects of treatments become more 
important for the individual. Quality of life is a multidimensional construct and 
health related quality of life (HRQoL) has in the context of healthcare been used 
to stress that it is the impact of health issues on quality of life that is of interest. 
It should be measured from the patient’s perspective as QoL might be interpreted 
differently by patients and caregivers47. For example, patients might be willing to 
accept certain burdensome treatment for only small to modest potential benefits. 
Nevertheless HRQoL has become a more important outcome measure in clinical 
trials48. The need for including patient reported outcome measures as primary 
endpoints in randomized controlled trials, has been identified, although few 
prospective trials have been conducted49, 50. 
 
Recovery after rectal resection  
Rectal cancer surgery has a negative effect on QoL51. Compared to surgery for 
colonic cancer, patients with rectal cancer appear to need longer time for recovery 
after surgery51, 52 regardless the use of open or laparoscopic surgical technique. 
Postoperative conditions such as bowel disturbances and low anterior resection 
syndrome (LARS) are recognized complications. Patients may also suffer from 
sexual and urinary dysfunction, due to damage to pelvic autonomic nervous 
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structures by preoperative radiotherapy or by surgery53, 54. Since the rectal 
resection itself has such an impact on patients, it has, using standardized and 
validated questionnaires, been difficult to differentiate the actual effect of the 
temporary ileostomy and if closure has a positive influence on HRQoL or not55, 
56. Even though reversal of a temporary ileostomy may lead to improved global 
QoL57, other symptoms, such as anterior resection syndrome, might reveal 
themselves as soon as bowel continuity is restored. 
 
Low anterior resection syndrome – LARS 
Major defaecatory problems frequently occur after rectal surgery, including 
constipation, stool incontinence, urgency, abdominal pain and increased 
flatulence58. The presence of these types of symptoms is referred to as low 
anterior resection syndrome. Between 40% and 80% of patients undergoing low 
anterior resection report severe postoperative bowel dysfunction within the first 
12 months59-62. According to a validated questionnaire the extent of LARS is 
divided into none-, minor- and major depending on the total score, using a scoring 
system63-65. Low anastomotic height, total mesorectal excision (in contrast to 
partial mesorectal excision), pre- and postoperative radiotherapy and a temporary 
stoma have been identified as risk factors for developing LARS or impaired 
anorectal function in the postoperative and long-term course61, 62, 66-68. As LARS 
is more frequently measured both pre- and postoperatively in patients in clinical 
practice, the prevalence is fairly well investigated69. Even though a longitudinal 
follow-up with LARS score is valuable, there is a lack of baseline information as 
patients’ preoperative scores involve the presence of a rectal tumour, which might 
cause symptoms similar to LARS. A recent Danish study investigated the 
prevalence of LARS in a normal population, which may be more accurate for 
comparison. The study found that between 10-15% of the general population 
suffered from major LARS, with higher prevalence in the ages 50-79 years and 
among women (with up to 19% prevalence of major LARS)70.  
Identifying, informing and treating low anterior resection syndrome requires 
multidisciplinary management. Treatment is empirical and symptom-based and 
includes pelvic floor training, rectal irrigation, bio-feedback therapy and 
neuromodulation with sacral nerve stimulation58, 71.  
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1.4 HEALTH ECONOMIC EVALUATION AND 
COST ANALYSIS 
 
The role and use of evaluating economics in health care has increased substantially 
around the world. Economic evaluations alongside randomized clinical trials are 
important sources of information for decision makers72. Healthcare resources are 
limited and decisions regarding allocation of resources must be made. Economic 
evaluation requires comparison of two or more alternative courses of action, 
while considering both the inputs (costs) and outputs (consequences) associated 
with each73. This is done by comparing costs and health effects of at least two 
alternatives, and can be done in four different models. The main difference 
between them is the measure of the health effect (table 1).  
 
Table 1. Measurements in different types of studies  
Model Description   
Cost-minimization 
analysis (CMA) 
Implies that two treatments achieve equivalent health effects 
and compares the incremental costs of two or more 
interventions.  
Cost-effectiveness 
analysis (CEA) 
Estimates incremental costs and health gains of alternative 
interventions. The clinical effectiveness is expressed in 
physical units; for example life years gained and can only 
compare interventions with the same specific measure of 
health effect. 
Cost-utility analysis 
(CUA) 
Takes into account the time spent in a health-state and the 
health related quality of life for that health-state. Expressed 
as quality-adjusted life years (QALYs). 
Cost-benefit analysis 
(CBA) 
Monetary value is assigned to the measure of health effect 
and the results can be compared to other interventions on 
different sectors of society. 
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Numerous guidelines recommend the use of cost-utility analysis with quality-
adjusted life years (QALYs) as the measurement of benefit. QALY is an outcome 
measure that combines quality of life and “quantity” of life lived, and one QALY 
can be viewed as one year lived in the best possible health state. It is also the most 
widely published form of economic evaluation73. The cost-utility analysis 
commonly uses the incremental cost-effectiveness ratio (ICER), which is the 
incremental cost divided by the incremental effect, resulting in the increased cost 
of the added effect (figure 4). This can be defined as cost per QALY gained and 
enables comparisons between interventions in all areas of health care. To 
determine whether an intervention is cost-effective or not relies further on the 
threshold of the maximum accepted level of cost-effectiveness. Usually there are 
national guidelines for thresholds, depending on the type of treatment. The WHO 
has suggested a threshold range of between 1 and 3 times gross domestic product 
(GDP) per capita, although the willingness to pay per QALY also depends on 
type of treatment (intervention), indication (condition or disease) and what the 
alternative treatment is74.  
 
 
 
 
 
 
 
Cost-effectiveness plane  
The ICER and willingness to pay threshold need to be carefully considered when 
an intervention is believed more effective and more costly. A way to explain this 
is through the cost-effective plane (figure 5). If the intervention is in quadrant B 
the choice of program is apparent, as it is more effective and less costly. The 
choice is also clear if the intervention is in quadrant D (less effective and more 
costly). In quadrants A and C the choice depends on the maximum cost-
effectiveness ratio one is willing to accept.  
Figure 4. The ICER is calculated using the formula above, where A represents the intervention and 
B the control/standard treatment.  
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Economic considerations within colorectal surgery 
Hospital costs associated with treatment of colorectal cancer are considerable. 
Tumours in the rectum (compared to colon), formation of a stoma and more 
advanced tumour stages at diagnosis lead to higher costs75, 76. Overall costs from 
healthcare perspectives are increasing, partly due to more advanced technology 
(laparoscopic and robot-assisted laparoscopic surgery)77, 78 but also due to 
improved survival including patients requiring palliative care75. From a societal 
perspective (including costs for sick-leave) there might however not be such a 
large difference between laparoscopic and open surgery77. A recent study 
including 7707 patients in routine Swedish care for colorectal cancer, found that 
laparoscopic surgery (compared to open) was favourable in terms of clinical 
effectiveness and costs, both from a societal and a health care perspective79.  
The formation of a temporary stoma is associated with costly events such as 
higher risk for readmission80, 81 and a second operation (stoma closure)75, 76. 
However, as discussed earlier in this chapter, since previous studies have strongly 
indicated clinical benefits from the use of a defunctioning stoma26, 29, this has been 
included in the standard surgical treatment. Furthermore as this strategy is 
associated with higher costs, despite cost savings due to less symptomatic 
anastomotic leaks76, early closure may be a cost-effective alternative82. 
 
Figure 5. Cost-effectiveness plane.  
 
In each quadrant (A-D), the 
intervention is: 
  
A: more effective, more costly 
B: more effective, less costly 
C: less effective, less costly 
D: less effective, more costly 
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2 AIMS OF THE THESIS 
 
The overall objective of this thesis and the EASY trial was to investigate the 
safety, feasibility and consequences of early closure of a temporary ileostomy after 
rectal resection for cancer.  
The specific aims for each study were: 
 
I. To compare early and late closure of a temporary ileostomy 
regarding surgical complications within 12 months after 
rectal resection. 
 
II. To evaluate health related quality of life within 12 months 
after rectal resection, comparing early and late closure. 
 
III. To perform a cost analysis 12 months after rectal resection, 
comparing early and late closure. 
 
IV. To investigate and evaluate bowel function four years after 
rectal cancer surgery, comparing early and late closure. 
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3 PATIENTS AND METHODS 
 
3.1 DESIGN OF THE EASY TRIAL 
 
The EASY trial 
The EASY trial was designed as a randomized, controlled multicentre trial83. It 
was set up in 2011 when early closure had only previously been studied in a 
randomized trial with several diagnoses42 and a pilot study41, both of which had 
identified the feasibility of early closure in selected patients with uneventful 
recovery after rectal resection. Eight centres from Denmark and Sweden 
participated in the EASY trial and patients were included from February 2011. 
Due to slower enrolment than anticipated, a recalculation of the sample size was 
performed, and with the revised sample size in mind the study was closed for 
inclusion in November 2014. Patients were randomized in computer generated 
blocks of six with a 1:1 ratio. All eligible patients were recorded in a screening log 
at the participating centres, reporting reasons for non-inclusion. A screening log 
including a representative sample of the target population at large is important in 
order to ensure external validity or generalizability in a study84. When inclusion of 
patients was complete, it emerged that three centres had inadequately reported 
the screening of all eligible patients. Before further analysis, the decision was made 
to exclude these centres, with the consequence that the intended number of 
patients was not reached, according to the sample size of 60 patients per group. 
A total of 112 patients were included, 55 in the early closure group and 57 in the 
late closure group.    
 
 
 
Figure 6. Time line of postoperative evaluation and inclusion process from rectal resection (day 0) 
to randomization (8 days). 
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Selection and inclusion of patients 
Screening for and inclusion of participants was made after rectal resection (index 
surgery) with creation of a temporary loop ileostomy (figure 6). Inclusion criteria 
were rectal resection for cancer with formation of a temporary ileostomy and age 
³ 18 years. Exclusion criteria were diabetes mellitus, steroid treatment and signs 
of postoperative complications or anastomotic leakage. Patients who were unable 
to understand the written Danish or Swedish language respectively, were not 
enrolled in the study. Details of the inclusion process has been described in the 
study protocol83.  
 
Follow-up  
Follow up of the different outcomes were up to 12 months for study I-III (figure 
7) and approximately 4 years for study IV, after rectal resection. Analysis was 
conducted in line with the intention-to-treat approach, meaning that the patients 
were analysed according to the group they were assigned, regardless of what 
treatment they received.  
 
 
 
 
 
 
 
Figure 7. Follow-up of outcomes up to 12 months after rectal resection (study I-III).  
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3.2 OUTCOME MEASURES 
 
The EASY trial explored three different outcome measures in the corresponding 
studies; morbidity and complications (primary endpoint), quality of life and cost 
analysis within 12 months after index surgery. Later, a separate study of functional 
outcome was added, including the surviving patients randomized in EASY, 
approximately four years after rectal resection (table 2). 
 
Table 2. Outcomes, measurements and follow-up of the different studies 
Study Outcome Measurement Follow-upa 
I Complications Clavien-Dindo 
classification, CCIâb 
Baseline, closure,     
3, 6, 12 months 
II Quality of life EORTC QLQ-C30, CR29, 
SF-36â 
3, 6, 12 months 
III Cost analysis Resource use 12 months 
IV Functional 
outcome 
LARS score,            
MSKCC BFIc 
Median 50 monthsd 
 
 
 
 
 
a follow-up specified as time from rectal resection (baseline) 
b comprehensive complication index 
c Memorial Sloan Kettering cancer center bowel function instrument 
d follow-up in October 2017 
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3.2.1 MORBIDITY AND COMPLICATIONS (I) 
 
The Clavien-Dindo classification of surgical complications 
The Clavien-Dindo classification of surgical complications85 is a system of grading 
postoperative complications based on the type of therapy that is required to treat 
the complication (table 3).  
 
 
The classification has been used to grade complications after surgery since the 
publication of the original article in 2004 and the use of the classification system 
has increased over time. The classification grading system has further been 
evaluated using patient case examples, revealing some differences in 
interpretation of the grading of complications among and between patients, 
nurses and doctors86. There were for example differences in interpretation of 
medical complications that were sometimes recognized as being unrelated to the 
Table 3. Clavien-Dindo classification of surgical complicationsa 
Grade I Any deviation from normal postoperative course 
Antiemetics, analgetics, diuretics, electrolytes, superficial 
wound infection (opened at bedside) 
Grade II Additional pharmacological treatment other than grade I 
   Blood transfusion, parenteral nutrition, antibiotics 
Grade III Requiring intervention (surgical, endoscopic, radiologic) 
   IIIa: intervention not under general anaesthesia 
   IIIb: intervention under general anaesthesia 
Grade IV Life-threatening complication 
   IVa: single organ dysfunction (including dialysis) 
   IVb: multiorgan dysfunction 
Grade V Death 
a simplified from the classification of surgical complications85, 86  
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surgical procedure. The overall recommendations are to classify all medical 
complications if they occur during hospital stay or within 30 days from surgery, 
even if they are considered being unrelated to the actual surgical procedure. If 
multiple complications occur, the recommendations are to only count the most 
severe one (if they are consequences from one another). However if the 
complications are independent, to grade them separately and take all into 
account86. 
Bearing this in mind, using the suggested recommendations, there are still 
difficulties in defining what a complication might be or when it is considered a 
“normal” postoperative course after extensive surgery, such as rectal resection. 
One example is the postoperative use of opioids. In the current study the 
complications were graded in the clinical report forms (CRFs) by the treating 
physician. All prospective data were also reviewed retrospectively in order to 
ensure that all complications were graded using similar definitions and not 
counted twice by mistake. Concerning the example of opioid use, if the patient 
had a prescription renewal, dosage increase at follow-up or if pain was described 
problematic for the patient, this was considered a complication in the present 
study. However there are no generally accepted strict definitions to follow.  
The loop ileostomy complications were also graded in the same system. For the 
less severe complications (grade I) such as skin irritation, leakage and small 
bleeding at the stoma, they were considered complications only if they were 
brought up as problems at least twice by the patient or caregiver. In the trial, 
follow-up of stoma function was provided by stoma care nurses. 
 
Comprehensive complication index 
Quality of life and postoperative complications are often reported as separate 
outcome measures, where QoL is usually reported by the patients, and 
complications by the surgeon or caregiver. A suggestion of a correlation between 
patient reported QoL and grade of complications, both of which seem to recover 
within 12 months in elective colorectal surgical patients, has previously been 
made51, 87. The Clavien-Dindo classification grades reflect the magnitude of each 
complication. However the system may not represent the entire burden of 
postoperative morbidity, as often only the complication with the highest grade is 
reported. The effect on patients with more than one complication may therefore 
be underestimated88. Thus, comparisons of patients with more than one 
complication are difficult; for example when comparing the morbidity of a patient 
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with four grade I and II complications with another patient experiencing one 
grade IIIb complication, is not a simple task.  
The comprehensive complication index (CCIâ) was developed in order to 
overcome these problems and integrate all recorded complications weighted by 
severity89. It is based on the Clavien-Dindo classification and summarizes the 
morbidity burden in a scale ranging from 0 (no complication) to 100 (death) 
(figure 8). 
 
 
When explored in randomized controlled trials, the CCIâ has indicated better 
sensitivity to detect differences between treatment effects. Furthermore, this 
suggests that the use might allow smaller sample size in future studies, as well as 
enabling longitudinal assessment of complications over time. When used in 
clinical trials with overall morbidity as endpoint, it could be considered as the 
primary outcome measure90.  
The EASY trial was designed before the CCIâ was in use. However, with regard 
to the added value of the comprehensive complication index as outcome measure, 
this was included as a supporting endpoint to the number of complications and 
their Clavien-Dindo classifications.  
Figure 8. Formula for calculation of the 
CCIâ and the weight of each corresponding 
Clavien-Dindo grade of complication.  
The CCIâ single value corresponds to the CCIâ 
of one complication with a certain Clavien-
Dindo grade. If for example a patient has one 
grade IIIa complication, the comprehensive 
complication index would be 26.2. 
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3.2.2 QUALITY OF LIFE (II) 
 
The importance of evaluating quality of life, or patient reported outcome 
measures, has increased and in clinical trials it is more commonly recommended 
to include QoL evaluation. It may even be the primary outcome of choice for 
trials(47), especially in the palliative care setting. Measurements and instruments for 
assessing QoL should satisfy basic properties if they are to be clinically useful. 
These properties are validity, reliability, repeatability, sensitivity and 
responsiveness. Validity describes how well a measurement represents the 
attribute being measured. Reliability and repeatability concern the random variability 
associated with measurements, where ideally patients with no change in status, 
should give similar responses each time they are assessed. Sensitivity is the ability 
of detecting differences between patients/groups and responsiveness relates the to 
the capability of detecting changes when a patient experiences improvements or 
deteriorations47. The validation of instruments is based on the process of 
determining whether the instrument measures what it is intended to measure, and 
subsequently if it’s useful for its intended purpose. 
In the QoL evaluation in the EASY trial, three validated questionnaires were 
included; European organisation for research and treatment of cancer (EORTC) 
questionnaires QLQ-C30 and CR29 (colorectal module), and Short Form 36 (SF-
36â) (see appendix). These questionnaires, divided into several items, give scores 
that make the longitudinal follow-up possible as well as comparison between 
groups of patients and to reference populations. However, often raised questions 
are: how large must a change or difference in QoL score be in order to be clinically 
important, and when is the difference between groups large enough to be 
noticeable? For example, regarding the EORTC QLQ C30, which is developed 
to assess QoL in patients with cancer, it has been suggested that 5-10 points 
difference should be considered as ‘little change’ and 10-20 points difference 
would represent a ‘moderate change’91. As for the SF-36â, other values are 
suggested in a similar manner92. 
 
Baseline assessment 
There should usually be a baseline/pre-treatment assessment for evaluation of 
change over time from when the treatment is introduced. This would also enable 
baseline comparison between the studied groups. The assessment should be made 
before the patients have been informed of group assignment in order to minimize 
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bias in questionnaire response47 and it is desirable to assess the patients at the 
same points in time in all treatment arms.  
 
Missing data 
The largest challenge concerning patient reported outcomes in clinical trials is 
compliance, which depends on several factors, including timing of assessment, 
type and severity of disease and treatment.  
Regarding QoL assessment, missing data is a 
recurring problem. At best, the pattern of 
missing data is not related to patient 
characteristics that influence the outcome. This 
is referred to as data missing at random, and the 
missing data would only render wider 
confidence intervals and reduced statistical 
power, but the estimated treatment effects 
would be unbiased. At worst, missing data 
would be related to factors influencing 
outcome. This is referred to as missing not at 
random. The missing data would then result in 
biased estimates of the treatment effect. It is 
important to understand the cause of missing 
data and if there is a pattern which could lead to biased results and incorrect 
conclusions. In general, if more than 50% of the data for a particular endpoint is 
missing, analysis is not recommended, while fewer missing answers can have 
minor to moderate impact on study findings. If there is less than 10% missing, a 
simple imputation may be sufficient93. A major problem regarding the EORTC 
QLQ-C30 occurred at 12-month follow-up in the trial, as a total of 36 patients 
were by mistake given an incomplete questionnaire lacking one page. This was 
equal to half of the questions. Due to the fact that data were missing at random, 
i.e. the missing values did not correlate to scores recorded in the QoL assessment 
(because of distribution of incomplete questionnaires), imputation was 
considered unnecessary47. Instead analysis of physical- and role functioning was 
performed and presented for the 12 month follow-up, as these functional scales 
were completely scored using the distributed questions (1-15), and were not 
affected by the missing page of the questionnaire.   
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Comparison of results 
Ideally, comparisons are conducted within and between the treatment groups 
from baseline and over time. Because of the design of the EASY trial, patients 
were included after their rectal resection and therefor no baseline, preoperative 
evaluation was available. In order to evaluate and to guide interpretation of results, 
comparisons with reference scores of general populations were made, as 
suggested47. In the trial, reference populations from Sweden94, 95 and Germany96 
were available and used for comparison, as supposedly these would be 
representative for the patients studied in Sweden and Denmark. 
 
 
3.2.3 COST ANALYSIS (III) 
 
The role and use of economics in healthcare has increased substantially around 
the world and economic evaluations alongside randomized clinical trials are 
important sources of information for decision makers97. Ideally, studies would be 
powered also for economic outcome measures, however this is rarely the case as 
sample sizes are usually based on primary outcomes alone. Consequently, the 
economic comparisons may be underpowered97. The costs can be analysed from 
the healthcare perspective and/or the societal perspective, the latter adding the 
cost of sick-leave to the direct healthcare costs. In Sweden data on sick-leave can 
be attained through the Swedish Social Insurance Agency. Since the EASY trial 
also included Danish patients (where sick-leave data were not available), the cost 
analysis it the study was only performed from the healthcare perspective. 
 
Identification of cost variables 
There are two ways of collecting and analysing data; either through micro costing, 
where all separate resource items are identified in great detail, or gross costing, 
where consumption of single resources is aggregated to meaningful resource 
units. Nevertheless, it is important to identify the potential key cost-driving 
events; usually those that either have a high unit cost or those with a small unit 
cost but occur at high frequency97. Furthermore it is also recommended to include 
costs that differ between treatment groups73. The cost analysis alongside the 
clinical trial had an intention to treat approach, as recommended97. Surgical 
treatment for rectal cancer is resource consuming. One might assume that it 
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would be less costly with an early closure of a temporary ileostomy, knowing that 
the presence of a stoma has a substantial influence on readmission rates and 
healthcare costs75-77, 80. The primary endpoint analysis showed significantly more 
complications, many of which were stoma related, in the late closure group. There 
was no difference in severe complications and/or number of reoperations98. Even 
though complications of all grades increase the costs of major surgical procedures, 
including colorectal surgery99, the impact of less severe complications on 
healthcare costs were unknown in the present study. Actual frequencies of 
readmissions and investigations were not evaluated as a primary outcome 
measure. The key cost-driving  resources that were identified prior to inclusion of 
patients and evaluation of data in the cost analysis are seen below (table 4). 
 
Table 4. Identified key cost-driving resources from the healthcare perspective 
Cost variable Reason for inclusion 
Rectal resection High unit cost, low frequency 
Stoma closure High unit cost, low frequency 
Reoperation High unit cost, low frequency 
Length of stay – readmission Medium unit cost, unknown frequencya 
Outpatient visit Low unit cost, high frequency 
Outpatient endoscopy Mediumb unit cost, unknown frequencya 
Outpatient radiology Mediumb unit cost, unknown frequencya 
Stoma appliances Low unit cost, high frequencyc 
 
 
 
 
 
a expected to be high frequency 
b varying cost depending on type of examination 
c predominantly in the late closure group 
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Unit costs 
The cost variables were derived from Swedish unit costs in order to eliminate bias 
in the sense that different countries apply different costs for equal treatment. 
Since complete data regarding all costs in association with procedures were not 
available through the clinical report forms, all inpatient surgical procedures were 
priced according to their corresponding diagnosis and performed procedure. The 
tariffs were based on national data covering approximately 85-90% of all inpatient 
procedures in Sweden (Swedish Association of Local Authorities and Regions). 
When available, national prices were used (surgical procedures), however for 
specific examinations, radiologic investigations, and outpatient visits, local unit 
costs from a university hospital were used. 
 
The importance and use of quality adjusted life years (QALYs) 
It is recommended that baseline data regarding HRQoL should be collected at 
point of enrolment, prior to the intervention in a study. QALY analysis should 
then be adjusted for any baseline imbalance. In the EASY trial, as mentioned 
previously, no baseline QoL data were obtained, which made adjustment 
impossible. Regarding the calculation of QALYs; the need of analysis of 
economic thresholds and the willingness to pay per QALY gained, is based on 
scenarios where either the intervention is more costly and more effective, or less 
effective and less costly. Concerning the results of the first and second study of 
the EASY trial, the intervention was found to be more effective (through the 
surrogate end point of complications up to 12 months after surgery) without any 
difference in QoL. If the intervention was believed to be more expensive, there 
would have been indication for calculation of QALYs and ICER (see chapter 1), 
but as there were no signs of increased resource use in the intervention group 
(early closure) a cost analysis was appropriate.  
 
Protocol-driven costs 
When conducting a cost analysis alongside a clinical trial there is a risk that the 
costs for the study population will be protocol-driven, by for example increasing 
the resource use through more surgical procedures, radiologic investigations or 
follow-up visits. This is particularly important if there is a difference between the 
intervention and the control group. In the cost analysis of the EASY trial we did 
not include the costs of the endoscopy and/or radiologic examination prior to 
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inclusion. However, patients allocated to the late closure group had in many cases 
undergone an extra endoscopy prior to stoma closure (since the former 
examination would’ve been carried out several months earlier). The consequence 
of this was that several patients in the late closure group had undergone two 
examinations of the anastomosis; prior to trial inclusion and prior to closure. This 
endoscopic examination was therefor considered protocol-driven and a decision 
was made to add the cost of an endoscopy in the intervention group as well as for 
the patients in the control group who had not undergone an extra examination, 
as a sensitivity analysis to address this problem.  
 
The non-parametric bootstrap  
Non-parametric bootstrapping is used when data are skewed and you need to 
describe the distribution of possible mean values. Through the use of resampling 
from the existing data with replacements, an empirical estimate of the sampling 
distribution of mean costs is generated73. In the cost analysis a non-parametric 
bootstrap analysis generating 2000 iterations was performed due to skewed data 
in order to assess robustness. 
 
 
3.2.4 FUNCTIONAL OUTCOME (IV) 
 
Four-year follow-up 
The functional follow-up was a separate study including the surviving patients 
randomized in the EASY trial and comprised two questionnaires, the LARS score 
and the Memorial Sloan Kettering cancer center bowel function instrument 
(MSKCC BFI). The LARS score was developed in Denmark and published 
originally in 201263. Inclusion of patients in the EASY trial took place between 
2011-2014, hence started before the LARS score was fully developed and in use, 
and consequently not included in a functional follow-up at the initial stage. Since 
there have been suggestions that a temporary stoma increases the risk of low 
anterior resection syndrome61, 67, it was considered out of interest to follow up the 
patients with regard to bowel function and investigate if there were signs of 
differences between the two groups, depending on timing of stoma closure. 
Questionnaires were therefor sent to all surviving patients in 2017, resulting in a 
mean follow-up time of 50 months after rectal resection.  
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Sample size 
Since the study was based on the cohort from the EASY trial, which was not 
designed for the endpoint in study IV, a post hoc sample size calculation was 
performed. A previous study on bowel function after rectal resection reported a 
mean LARS score of 25, with a standard deviation of 12100. Corresponding value 
for the general population was approximately 15, with a standard deviation of 
1270. This corresponds to a difference in LARS score of 10 units. With 25 patients 
per group we would have 80% power to detect a difference of 10 units, at a 5% 
significance level.  If however we would anticipate smaller difference in LARS 
score (since both treatment groups have undergone rectal resection), we would 
have 80% power to detect a difference of 5 units with approximately 90 patients 
per group.  
 
Questionnaires 
The LARS score consists of five questions, where different questions have 
different weight based on the impact on QoL. Depending on score, the results 
are divided into no, minor or major LARS. The BFI is more detailed, containing 
18 questions. Both questionnaires have been validated63, 101. The LARS score was 
available in Danish and Swedish, whilst the BFI was available in English and 
translated into Danish and Swedish through a forward and backward translation 
procedure, for study IV. A recent study has evaluated the prevalence of LARS in 
a normal Danish population70, which enables comparison to a reference 
population, as described in the first chapter. Unlike the BFI, the LARS score has 
since publication been adapted widely into routine care of rectal cancer patients, 
as it is considered a simple instrument enabling longitudinal follow-up. 
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3.3 METHODOLOGICAL CONSIDERATIONS 
 
The randomized controlled trial design 
The first randomized controlled trial was conducted in the mid 1900s. This type 
of study has the last 20-30 years emerged to be considered providing the highest 
grade of evidence when evaluating a new therapy. Systematic reviews and, even 
better, meta-analyses of several RCTs102 should show the new intervention to be 
superior compared to clinical routine, before systematic implementation of the 
new therapy is considered. In randomized controlled trials it is desirable to restrict 
participants to a near-homogenous group, which will reduce the outcome 
variability, consequently reducing the sample size needed in order to obtain 
statistically significant differences. A consequence is however that the trial might 
end up evaluating only small subsets of potential populations of interest hence 
questioning the external validity, generalizability and decreasing the applicability 
of the research results103. In contrast, observational studies might include broad 
populations and generalize well, however there are issues regarding internal 
validity and unknown quantity of confounders and their effects.    
 
There are a few major sources of error in clinical research to consider104. 
Selection bias results from one or several non-random elements that influence the 
allocation of patients to exposures in a way that will influence the outcome. A 
randomized trial will minimize this problem. It is however vital to follow the 
randomization process and maintain a screening log, in order to reduce selection 
bias.  
Confounding is when an apparent association between exposure and outcome 
actually results from their separate relationships with something else 
(confounder). The randomized design will randomly and evenly allocate the 
patients and hence the confounder. This will not only divide the influence of the 
confounder evenly, but also implies that you don’t always have to identify all 
potential confounders. In practice, a situation can occur when the groups are not 
similar despite randomization. You can then perform sensitivity adjusted analyses 
for specific variables in order to minimize the effect of a confounder on the 
results. Block randomization can be performed in order to minimize the impact 
of site-related variations that are assumed to be a substantial potential 
confounder103, 105. 
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Measurement bias results from non-random errors in assessing exposure and/or 
outcome (disease). Thoroughly designed study protocols and clinical report 
forms, where the objectives are to standardize data quality, can enhance the 
quality of the measurements. To minimize bias further, blinding is a possibility. 
Blinding can be difficult to achieve in surgical studies because of the nature of 
interventions. However some studies have achieved this by for example using 
standard surgical dressings in order to conceal laparoscopic or open approach in 
abdominal surgery, both to the patients and the investigators assessing the 
patients106.  
Overall the randomized study design minimizes selection bias and, in sufficiently 
large studies, ideally prevents confounding. To fully prevent measurement bias, 
however blinding would be required. Studies fulfilling these requirements, 
randomized, blinded clinical trials with sufficient number of patients provide the 
most valid clinical research results103. 
 
 
3.4 STATISTICAL ANALYSIS 
 
Statistical models 
A large body of empirical research, including clinical studies, involves the aim of 
explaining to what extent different factors (effects), including therapeutic 
interventions, can explain variability in outcome. This is done by statistical models 
that aim to quantify the contribution of each factor, as well as the part one can’t 
explain (the residual term consisting of random variation). Assuming that the 
factors and the random variation contribute to the outcome according to a linear 
model, makes estimation and interpretation easier. One key component in 
parameter estimation is the specification of a probability distribution for the 
randomness in the data. A broad class of statistical models, referred to as 
generalized linear models107, consist of two components; a probability distribution 
for the randomness in the data and a link function that specifies at what scale the 
effects contribute linearly. Generalized linear models allow a broad class of 
different probability distributions, including the normal, binomial and Poisson 
distribution. Different link-functions are suitable for the different distributions. 
The different link-functions do in turn mean that the contribution of the effects 
to the outcome on the linear form, are done at different scales than for the 
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outcome. For the normal distribution, the identity link is suitable, meaning that 
no change in scale is needed and the effects are quantified at the same scale as the 
original measurement. For the binomial distribution the logit or log links are 
suitable; for the effects to be interpretable on the original scale (risk or probability 
for an event) the results are presented as an odds ratio. 
When a reasonable statistical distribution and a link-function are specified, a 
generalized linear model enables a unified framework for the estimation and 
interpretation of treatment effects. However, for a large body of data in clinical 
research the assumptions required for a generalized linear model may be 
questionable. This occurs for example when data have skewed or multimodal 
distribution (more than one mode) or extreme values, where determining a 
reasonable distribution is not possible. In these cases, a generalized linear model 
is not considered appropriate and a non-parametric method may be used. Non-
parametric methods require less stringent assumption regarding the data. 
However the methods are mainly limited to hypothesis testing where only p-
values are obtained with no interpretable quantification of treatment effects, for 
example the average difference between treatment groups. In the EASY trial, a 
generalized linear model was used for study I and III, but non-parametric 
methods were used in study II and IV, as data were skewed and included extreme 
values.  
 
Sample size 
When planning a study one needs to determine the number of patients required 
to reach a sufficient statistical power. If a difference, of a magnitude that is of 
interest, truly exists between treatments (intervention and control), sufficient 
amount of information (number of patients) is required in order to have a good 
chance of detecting it. In other words, sufficient statistical power is required to 
detect a clinically meaningful treatment effect (the chance of rejecting the null 
hypothesis when a certain alternative that we aim to detect, is true). Besides 
deciding a clinically meaningful difference, the sample size calculation also 
depends on the level of the anticipated variability (or the incidence rate) in the 
data and the risk of a type I error (risk of incorrectly rejecting a true null 
hypothesis) one is willing to take. The clinically relevant difference which one 
would like to detect (if it is present), can arise from previous published data, 
alongside clinical experience105. However, this becomes a challenge when there 
are no previous data available.  
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The trial was powered for the primary outcome (study I), but power calculation 
was also executed for QoL (study II), where previously described minimally 
clinically important differences were used, both for the SF-36â and the EORTC 
QLQ C30.   
 
Multiple hypothesis testing 
In the framework of statistical hypothesis testing, two types of errors can be made; 
type I (falsely rejecting a true null hypothesis) and type II (failing to reject the null 
hypothesis when the alternative hypothesis is true). The risk of type II error 
depends on the statistical power. The error rates are controlled by having a fixed 
risk of type I error, usually set to 5%, and the type II error is minimized by 
increasing the sample size. When performing several hypothesis tests the risk of 
making at least one erroneous decision will be larger than 5%. This error is called 
the familywise error108. The more tests that are made, the higher the familywise 
error rate will be. There are different strategies available for having the familywise 
error rate set to remain at 5% when several hypothesis tests are performed. The 
different strategies depend on whether all tests are of equal importance (referred 
to as parallel procedures) or if we have an order of priority (referred to as fixed 
sequence procedures),  for example if some endpoints are of more interest than 
others. One strategy is to inflate the p-values, making it more difficult to reject 
the null hypothesis at the pre-specified significance level, e.g. 5%, by using 
methods for multiple testing. One parallel procedure is the Bonferroni correction, 
where each p-value is multiplied by the number of planned tests. One fixed 
sequence procedure is to only test a secondary hypothesis if the primary is 
rejected. In study I some of the hypotheses were of equal importance and some 
were of higher priority. The strategy used was a combination of parallel and fixed 
sequence procedures (referred to as gatekeeping procedures) where the two 
secondary hypotheses were only tested at 2.5% level if the primary hypothesis was 
rejected at the 5% level.  
The seriousness of the increase in familywise error rate depends on the scientific 
objective. In early phases of the study of new therapies where the objective is 
characterized as explorative and hypothesis generating, or for secondary and 
tertiary endpoints in a clinical trial, correction for multiple testing may not be 
necessary. But for the primary objective of confirmatory studies, a correction for 
multiple testing may be needed.    
 
Early Closure of a Temporary Ileostomy after Rectal Resection for Cancer  
 28 
3.5 ETHICAL CONSIDERATIONS 
 
Safety 
The trial included patients undergoing surgery with risk of complications, 
anastomotic leakage being one of them. Even though the integrity of the 
anastomosis was confirmed prior to inclusion in the trial, there was still a small 
risk for “late” leakage and consequently a risk that these patients would benefit 
from a stoma during a longer period, exceeding two weeks. The primary aim was 
to investigate safety of early closure, hence the narrow inclusion criteria with the 
consequence of only selecting patients without any signs of postoperative 
complications or considerable comorbidity. However, with regard to known 
complications and morbidity associated with a temporary ileostomy and the 
importance of an early closure, the potential benefits outweighed the risks, and 
the study was therefor designed accordingly.  
 
Ethical approval and data security 
The trial was approved by the Science Ethical Committee for the capital region 
in Denmark (protocol id: H-1-2010-113) and in Sweden the project was approved 
by the Regional Ethical Review Board in Gothenburg (Dnr 064-2011). For the 
functional follow-up (October 2017), ethical approval was achieved in Denmark 
and Sweden. The trial was approved by the Data Protection Agency in Denmark, 
and by the Personal Data Representative at the Sahlgrenska University Hospital, 
Göteborg, Sweden. Before inclusion, patients were informed about the study and 
all participating patients returned a signed consent form.   
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4 RESULTS 
 
4.1 COMMON FINDINGS 
 
During the inclusion period, 418 patients were identified and assessed for 
eligibility. Of these, 291 did not meet inclusion criteria, where 37 had a suspected 
anastomotic leakage. Randomization was performed in 127 patients but was 
followed by further exclusions (the larger part being due to exclusion of centres 
that failed to maintain a screening log, as described in chapter 3), and in the end 
55 patients were allocated to early closure, and 57 to late closure. See figure 9 for 
details.    
Figure 9. Participant flow diagram showing enrolment, allocation, follow-up and analysis of patients 
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Reasons for exclusion 
Approximately 70% of the patients who were assessed for eligibility did not meet 
inclusion criteria (figure 9). Some of these were due to medical reasons (n=159). 
Patients who had undergone different types of surgery than rectal resection with 
the formation of a temporary ileostomy constituted a large proportion (28%). 
Postoperative complications such as paralytic ileus, infection and reoperations, as 
well as diabetes were other causes for non-inclusion (table 5).  
Table 5. Medical reasons for non-inclusion 
Medical cause Number of patients 
Permanent or no stoma (including Hartmann’s procedure) 45 (28%) 
Diabetes 28 (18%) 
Paralytic ileus 24 (15%) 
Delayed postoperative recovery 15 (9%) 
Perioperative complications 7 (4%) 
Reoperation 7 (4%) 
Other infection 5 (3%) 
High stoma output 5 (3%) 
Language difficulties 5 (3%) 
Extensive cancer disease 3 (2%) 
Steroid treatment 3 (2%) 
Cardiovascular disease & pulmonary embolism 3 (2%) 
Ulcerative colitis 1 (1%) 
Other 8 (5%) 
Total 159 
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There were 37 patients with suspected anastomotic leakage (corresponding to 
approximately 9% of the 418 assessed patients) and some 53 patients (13%) were 
unwilling to participate, with further three patients withdrawing consent after 
randomization. 
 
Response rates 
Although the trial and the four studies in this thesis were based on the same 
patient population, sources of information (CRF data and questionnaires), 
outcome measures and follow-up times were different. The total number of 
patients analysed at each follow-up occasion varied (participant flow diagram 
presented in each study), but were overall high. Patients available for follow-up 
and response rates for patient reported outcome measures (study II and IV) are 
seen in table 6.  
 
Table 6. Data source and response rates for each studya 
Data source and 
study 
Early closure 
(n=55) 
Late closure 
(n=57) 
Time of follow-up 
(from rectal resection) 
CRF    
Study I 55/55 (100%) 57/57 (100%) Closure, 3, 6, 12 months 
Study III 55/55 (100%) 57/57 (100%) 12 months 
Questionnaires    
Study II 52/55 (95%) 53/57 (93%) 3, 6, 12 months 
Study IV 42/47b (89%) 40/46c (87%) Median 50 months 
(range 34-77 months) 
 
 
 
 
a response rates refer to the number of patients with data from at least one follow-
up occasion for each study 
b patients available for follow-up (n=47); deceased (n=7), permanent stoma (n=1) 
c patients available for follow-up (n=46); deceased (n=5), permanent stoma (n=6) 
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Patient characteristics  
Patient characteristics at baseline are presented in a table in each study. Overall 
the patients were comparable regarding age, body mass index (BMI), comorbidity, 
radiotherapy (including long-term), adjuvant chemotherapy, employment and 
educational level. The early closure group had more women (n=31) compared to 
the late closure group (n=21). Tumour height differed slightly with higher 
tumours in the late closure group. There were also somewhat more patients with 
clinical stage I of their cancer disease, according to the Union for international 
cancer control (UICC), in the late closure group. At the functional evaluation 
approximately four years after rectal resection, the difference in sex, tumour 
height and clinical stage of cancer disease persisted between the groups. At this 
follow-up there was a larger proportion of patients in the late closure group who 
had been treated with adjuvant chemotherapy, although the differences were 
small.  
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4.2 MORBIDITY AND COMPLICATIONS (I) 
 
The main outcome for the first study in this thesis was the mean number of 
complications after rectal resection within 12 months. CRFs were collected at 
baseline (after inclusion), at stoma closure and at 3, 6 and 12 months respectively. 
All complications within 12 months were registered, including stoma related 
complications that were registered retrospectively by inspection of patient charts. 
The Clavien-Dindo classification of complications was used to grade all 
complications and the CCIâ was applied as a supporting endpoint. 
The mean number of complications per patient was 1.24 in the early closure group 
compared to 2.88 in the late closure group, with a mean ratio for intervention 
versus control of 0.42 (95% CI: 0.32-0.57). The difference was statistically 
significant with a p-value of <0.0001. Regarding CCIâ level, there was a median 
difference of 15.7 units (8.7 and 24.4 for early and late closure group 
respectively)98.  
There was no difference regarding more severe complications (Clavien-Dindo 
grade IIIa or higher), including reoperations. There were more stoma related 
complications in the late closure group, and the median for the duration of the 
loop ileostomy was 11 days and 148 days in the early and late closure group 
respectively. 
Sensitivity adjusted analyses were performed with sex, age, BMI, comorbidity and 
radiotherapy as covariates, and did not alter the results.  
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4.3 QUALITY OF LIFE (II) 
 
In the second paper the aim was to compare QoL and disease-specific quality of 
life between the two groups, at 3, 6 and 12 months after index surgery109. The 
questionnaires included the SF-36â, EORTC QLQ-C30 and CR29 (the latter 
more specific for colorectal cancer).  
An printing error lead to a low response rate regarding the EORTC QLQ C30 at 
12 months (55%), whilst response rates were otherwise 82-95%.  
SF-36â scores were similar with no difference in physical or mental component 
scores. All dimensions improved over time. At 3 months a majority of patients 
scored values below mean levels of the reference population94 while at 12 months 
scoring higher than the reference population, with physical functioning yielding 
the highest scores among the dimensions.  
EORTC QLQ C30 and CR29 scores were comparable between the early and late 
closure group. 
The results indicated that global quality of life generally improved in the later part 
of the follow-up period (6-12 months), and at 12 months the results were 
comparable, not only between the two groups but also to age-matched reference 
populations as well as previous findings56, 95, 96. 
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4.4 COST ANALYSIS (III) 
 
The resource use analysis was carried out at 12 months after rectal resection. All 
data were collected through CRFs and for the analyses, unit costs were derived 
from Swedish sources and applied for all patients. All costs were adjusted to the 
price year of 2016 and analysed from the health care perspective.  
The total difference in mean cost per patient was 4060 USD ($) in favour of early 
closure (95% CI: 1121-6999). The difference was found statistically significant 
with a p-value of <0.01.  
Sensitivity analysis (as described in study III and in chapter 3) and adjustment for 
sex, comorbidity, BMI, age and radiotherapy did not alter the results. To test 
robustness a non-parametric bootstrap analysis based on 2000 iterations was 
performed, showing similar findings.  
In summary, the predominant cost affecting factors were reoperations, 
readmissions and endoscopic examinations. Readmission rates had not previously 
been investigated in the EASY trial, and the present study showed that 24% of 
the patients in the early closure group were readmitted to hospital within 12 
months after surgery while 49% of the patients in the late closure group were 
readmitted (excluding the readmission required for stoma closure).  
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4.5 FUNCTIONAL OUTCOME (IV) 
 
Another secondary analysis of the trial was long-term functional outcome. 
Questionnaires LARS score and MSKCC BFI were sent to patients in the autumn 
of 2017, yielding a median follow-up time of four years.  
Overall 54 patients (66%) reported major LARS and 16 (20%) reported no LARS. 
There was no difference in median LARS scores between the groups and the 
prevalence of LARS (minor and major) was 76% and 85% in the early and late 
closure group respectively (RR: 0.89, 95% CI: 0.72-1.11, p=0.29).  
Median BFI scores did not differ between the groups. The patients in the early 
closure group reported less urgency with a median urgency subscale score of 17, 
compared to 14 for the late closure group (p=0.02). 
There was an observed difference in permanent stoma occurrence at follow-up; 
one patient in the early closure group and six patients in the late closure group, 
however the difference was non-significant. 
Tumour height and use of radiotherapy (known risk factors for LARS) were 
included as covariates in adjusted analysis, and did not alter the findings. 
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5 DISCUSSION 
 
5.1 DISCUSSION ON FINDINGS 
 
The randomized controlled trial found that early closure of a temporary ileostomy 
in selected patients was superior in terms of the primary outcome; number of 
complications up to 12 months after rectal resection. The null hypothesis could 
therefore be rejected.   
 
Complications and cost analysis 
Not only was the number of complications per patient fewer, but there were also 
fewer patients with any grade of complication in the early closure group, 
indicating an even distribution of complications among the patients. This 
difference persisted and there was a pattern of more severe complications in the 
latter part of the follow-up period, 6-12 months, in the late closure group98. 
Compared to a previous RCT42, the 3-month morbidity was similar (complication 
rates approximately 30-45%), which is also comparable to reported rates on 
national level after resection of rectal tumours110. However in the EASY trial, it 
seemed as if the difference in complications/morbidity between the two groups 
was more pronounced at 3-12 months, which had not been studied previously. 
This could of course be the consequence of the presence of a loop ileostomy 
(median time with ileostomy in the late closure group was approximately 5 
months). Further, in the cost analysis and the calculation of resource use, the 
readmission rate was found twice as high in the late closure group. Many 
readmissions were due to stoma related complications such as dehydration, and 
there was a difference already within 90 days from surgery with readmission rates 
of 24% and 35% in the early and late closure group respectively. This is slightly 
higher than previously reported81. Although severe complications did not differ 
between the groups, the burden of stoma related complications was evident in the 
median CCIâ score with a difference of 15.7 units, which is considered clinically 
relevant 90.  
Two meta-analyses have been published on the subject, one of which had overall 
postoperative morbidity as primary endpoint45 whereas one111 had anastomotic 
leakage. In the included RCTs42, 98, 112 anastomotic leakage was one of the 
exclusion criteria and radiologic examination of the anastomosis was undertaken 
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before inclusion in the studies. In both meta-analyses, increased number of 
surgical wound infections at the stoma site have been reported following early 
closure. In the EASY trial, we did not see the same infection rates nor a difference 
between the groups, which perhaps is due to the fact that, by routine practice, 
most skin closures, in connection with stoma reversal, are executed with a purse 
string suture technique. This has previously been suggested to decrease surgical 
site infections after stoma closure113. 
The cost analysis identified reoperations, endoscopic examinations and 
readmissions as the predominant cost affecting factors. Even though a sensitivity 
analysis was performed, the difference still prevailed. Colorectal surgery is 
associated with rather high complication rates, and complications, as well as 
readmissions, are in turn linked with higher costs80, 99. Even though directs costs 
from a healthcare perspective were analysed, we lack information on indirect costs 
from a societal perspective. Considering the higher readmission rate, the costs for 
sick-leave could be believed to be higher in the late closure group, with 
approximately 45% of the study population being employed, even though the 
median age was 67 years. This was however not investigated in the trial. 
Overall, with complications as a measurement of effectiveness, less complications 
lead to lower costs, and it is considered as an economically “dominant” strategy114. 
This is in line with the findings of the morbidity and cost analysis of the EASY 
trial.   
 
Patient reported outcomes – QoL and functional outcome  
Secondary analyses included assessment of QoL and functional outcome, the 
latter comprising a cross sectional prevalence study at median 4 years after rectal 
resection. The results indicated that global quality of life generally improved 
between 6 and 12 months, and at 12 months the results were comparable, not 
only between the two groups, but also to age-matched reference populations94-96 
as well as to previous findings56. The hypothesis of the QoL assessment; that there 
would be a difference in patient reported QoL with regard to the duration of the 
temporary stoma, was not proved in this study.  
Thresholds for clinical importance of four domains in the EORTC QLQ C30 
(including physical functioning and emotional functioning) have been suggested, 
based on a Dutch study including 548 patients with cancer115. In comparison, 
patients in the EASY trial had higher scores on the function scales. However 
when comparing the study populations, there were mixed cancer diagnoses and 
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more patients with advanced cancer stage (UICC III-IV) in the Dutch study, 
compared to the EASY population. One could also assume that the EASY 
population to greater extent were under curative treatment and this might affect 
both physical and emotional functioning. It has been difficult to detect clinically 
important differences as well in the QLQ C30 and the corresponding colorectal 
module (CR29 or the former CR38) with regard to stoma closure and stoma 
related complications56, 91. It has been suggested that patients with rectal cancer 
need longer time for recovery compared to patients with colon cancer51, 57 and 
that baseline QoL (in particular physical functioning) is a strong predictor for 
both survival and recovery57. One of the most important weaknesses of the QoL 
assessment in the EASY trial is the lack of baseline data, which limits the analysis 
and interpretation of data. Furthermore, being a secondary endpoint, with regard 
to the power calculation performed for the QoL assessment109, the study probably 
needed more patients for the relatively small differences one could expect 
between the groups, both of which had patients that had undergone major 
abdominal surgery for life-threatening disease. 
In contrast to the QoL assessment questionnaires QLQ C30 and CR29, baseline 
measurement of LARS at the time of diagnosis is often a poor estimate of a 
patient’s true function, as it may be severely affected by the rectal cancer70. 
Therefor comparison with normative data may be more beneficial. A recent 
Danish study evaluated the prevalence of LARS in a general population, with 1875 
patients responding to the questionnaire70, resulting in a general response rate of 
54.5%, but considerably higher (70.5%) in the ages 50-79 years, corresponding to 
the median age in the EASY trial. There was no difference in participating number 
of men or women in this age span, and the study showed that almost 20% of the 
studied female population suffered from major LARS. Considering this, we 
performed a post hoc sensitivity analysis, adjusting for sex, which showed similar 
results and did not affect the outcome. The high prevalence of major LARS in a 
normal population reflects that there are other common problems/diagnoses that 
affect bowel function, including irritable bowel syndrome, neurological disorders 
and previous vaginal childbirth. A further analysis may have been possible in the 
EASY trial, if data regarding risk factors such as these would have been available.  
The results of the functional outcome indicate that a substantial proportion of the 
patients suffered from severe bowel dysfunction many months after ileostomy 
reversal, and that there was a strong correlation between the patient reported 
outcome scales LARS and MSKCC bowel function instrument. Since the 
questionnaires regarding QoL (which offer a longitudinal assessment at 3, 6 and 
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12 months) and bowel function (cross sectional prevalence assessment) were 
conducted at different time points (1 year versus 4 years) it is not possible to 
correlate the patients’ reported outcomes to one another. This would’ve been 
interesting, in order to assess if the relatively high major LARS prevalence does 
in fact reflect on patient reported QoL, or perhaps the QoL assessment is too 
blunt to pick up on bowel symptoms in a population size equivalent to the one 
of the EASY trial.     
 
 
5.2 METHODOLOGICAL CONSIDERATIONS  
 
Potential bias 
The EASY trial, designed and conducted as a multicentre RCT, and with a study 
protocol83 clearly stating inclusion criteria and requiring a screening log, are all 
considered as strengths with regard to risk for bias. 
As mentioned previously in chapter 3, randomization is a method of ensuring that 
no bias is present in the allocation process. Further, this would ideally evenly 
distribute potential known and unknown confounders. In the EASY trial we came 
across the problem of an uneven distribution of sex, with more female patients 
in the early closure group. We did perform sensitivity adjusted analyses for 
specific variables, including sex, in order to compensate for unequal distribution. 
An option for future studies would be to stratify the randomization for sex and 
even for other factors of interest. With regard to the functional outcome, where 
women aged 50-79 years have reported worse function in a normative 
population70, stratification may have led to a larger difference between the groups, 
as the early closure group had a tendency of lower LARS scores, fewer patients 
with major LARS and were also in the group with more women, i.e. more prone 
to higher LARS prevalence. As for the functional follow-up, there was also a 
difference in permanent stoma prevalence (higher in the late closure group). This 
could represent a selection bias, as these patients suffered from anastomotic 
leakage, stenosis and bowel dysfunction (table 1 in study IV). We were by nature 
not able to assess these patients with regard to bowel function and presence of 
LARS at the time of follow-up. 
We made a decision, prior to analysis, to exclude patients from three centres based 
on the absence of complete screening logs, which was considered essential in 
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order to minimize selection bias. Being a trial with multicentre design, block 
randomization was performed in order to reduce the impact of site-related 
variations, considered as potential confounders103. 
Blinding was not possible for this trial, and there is therefore a risk of 
measurement bias. Even though there was a thoroughly designed study protocol 
prior to data acquisition, we still identified the need of adding a stoma specific 
CRF, after the patients were included in the study, but prior to analysis. This could 
be considered a weakness, as this data was retrospectively obtained, but was 
crucial in order to collect necessary data on stoma related complications. The fact 
that one author examined all coding of complications, in order to ensure that no 
complications were coded twice and that coding was consistent, is considered a 
strength with regard to internal validity of the trial and its primary outcome.  
One might argue that our careful selection of patients was a bias and consequently 
affected the external validity. The inclusion criteria, strictly limiting study 
participation to patients with an uneventful postoperative course, most certainly 
contributed to reduced variability. However, given the risk and potential 
consequences of reversing a stoma in a patient with anastomotic leakage, as this 
could be potential life-threatening complication in a frail patient, narrow inclusion 
criteria were necessary. Thus early closure of a temporary ileostomy is suggested 
to only be relevant in these selected patients.  
 
Representability and generalisability 
When conducting a study it is important to consider the generalisability and 
representability of the included patients, with regard to the target population. If 
we look at the characteristics of the patients in the EASY trial, they were slightly 
younger than patients with newly diagnosed rectal cancer in Sweden (67 years 
compared to approximately 70 years)116. Regarding severity of the cancer disease 
(measured in percentage of patients undergoing adjuvant chemotherapy), this was 
fairly similar compared to the Swedish oncological registry (40% in the study 
population compared to 40-70% for patients <75 years of age with stage III rectal 
cancer disease)117. Thirty-day postoperative complications were lower in the 
Swedish colorectal cancer registry (although only Clavien-Dindo grade II and 
higher were registered), but readmissions within 30 days from surgery, 
corresponded quite well with the study population (31% in the registry vs 24% 
and 35% in the early and late closure group respectively). Supposedly if grade I 
complications were registered in the registry the complication rates would be 
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more similar. It is however important to acknowledge that the Swedish colorectal 
cancer registry records all operated patients, including the patients undergoing 
abdominoperineal excision, Hartmann’s procedure and resection. One reason for 
lower age in the EASY trial is probably the strict inclusion criteria. The fact that 
only patients who had undergone an anterior resection with a primary 
anastomosis were included, compared to perhaps older and more frail patients 
where you do not consider an anastomosis because of the potential complications, 
represents a difference in the studied population. Additionally, patients with 
diabetes or delayed postoperative recovery may also represent more comorbid 
patients (table 5), and this represents a selection. Nevertheless, as described 
previously, the selection of patients was deliberate, with regard to patient safety. 
The multicentre design and block randomization were important for the 
generalisability with regard to the participation of hospitals with different volumes 
of rectal cancer surgery, representing standard care. 
 
Intention-to-treat analysis  
The intention-to-treat approach means that the patients retain their group 
allocation, even though the clinical course departs from the assigned treatments. 
In other words, keeping the analysis to intention-to-treat protects against 
exaggeration of true treatment differences, at the expense of  potentially 
underestimating treatment effects and diminishing study power103. The intention-
to-treat analysis almost always would result in a conservative estimate of effects 
of the new and tested intervention. The alternative, per protocol analysis, would 
place the patient at analysis in the group with the actual treatment received. This 
may exaggerate the difference of the compared treatments in favour of the new 
intervention. In the EASY trial there was one patient in the early closure group 
who had a late closure, due to failed attempt at early closure. This patient was 
analysed according to intention-to-treat and consequently the failed closure 
attempt was considered a complication and a reoperation.  
 
Measurement of treatment effects   
The trial comprised three subsets of outcomes; complications, resource use and 
patient reported outcomes. The two former (complications and resource use, 
corresponding to study I and III), are based on completeness and accuracy of the 
clinical report forms and, especially complications, often comprise primary 
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outcomes in clinical studies. The methods used for these measurements have been 
described previously (chapter 3). Regarding the patient reported outcomes, QoL 
and bowel function assessment (study II and IV), the measurements are more 
complex. As described earlier, in QoL assessment, it is preferable to compare pre-
treatment to post-treatment evaluations, particularly since this will reflect the 
changes in each patient more directly47. In EASY, pretreatment assessment was 
not included, and the remaining alternative was to compare to a normative 
reference population. This also limited the opportunity of baseline comparison 
between the treatment and control groups. Even though other characteristics 
such as age, cancer stage, adjuvant chemotherapy treatment and comorbidity were 
similar between the groups, this does not necessarily mean that patient reported 
QoL was.  
Regarding LARS score, the lack of baseline assessment was not necessarily a 
disadvantage, as preoperative values are less prone to be representative of the 
patients true, pre-rectal cancer baseline, as described previously70. However, with 
regard to the progress in LARS after rectal resection, even though symptoms 
often improve over time, assessing the bowel function through LARS score 
would have been optimal on a yearly basis. This in order to pick up on severe 
symptoms that may lead to surgical intervention (permanent stoma), even fairly 
shortly after rectal resection. As the scoring system was originally published in 
201263, there will certainly be more longitudinal follow-up studies on the 
prevalence of low anterior resection syndrome after rectal cancer surgery in the 
near future.  
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6 CONCLUSIONS 
 
Early closure (8-13 days) of a temporary ileostomy after rectal resection for cancer 
resulted in a significantly lower mean number of complications compared to late 
closure (>12 weeks), with a follow-up of 12 months. 
Early closure was safe and there were few severe complications in both treatment 
groups.   
Costs from a health care perspective correlated with the burden of postoperative 
complications. Early closure was associated with less use of outpatient resources 
as well as fewer readmissions, resulting in significant cost reduction compared to 
late closure. 
Quality of life generally improved up to 12 months after surgery, but did not seem 
to correlate with the clinical advantages of early closure, in comparison to late 
closure.  
A substantial proportion of patients suffered from severe bowel dysfunction 
several months after ileostomy closure. There was no statistically difference in 
prevalence of low anterior resection syndrome between the groups. 
 
Overall conclusion 
In selected patients, without signs of postoperative complications and certain 
comorbidity, early closure of a temporary ileostomy after rectal resection for 
cancer is safe and clinically advantageous. 
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7 FUTURE PERSPECTIVES 
 
The results of the trial have led to implementation of early closure in selected 
patients. A routine document has been established, with the strict inclusion 
criteria of the trial retained in practice. In order to follow up on results, assuring 
that the outcomes of the trial also translate into practice, ethical consent to follow-
up on patients treated with early closure after rectal resection for cancer, has been 
approved by the Regional Ethical Review Board in Gothenburg (Dnr 834-17).  
Since early closure has not been studied to the same extent on other patient 
categories that may benefit from the procedure, such as patients with 
inflammatory bowel disease who receive an ileo-anal pouch anastomosis with a 
temporary ileostomy, the procedure cannot be recommended more widely as of 
now. However, with growing experience of early closure, future studies may be 
designed also to include a wider group of patients (compared to the strict 
inclusion criteria of the trial), and more diagnoses. The optimal timing of stoma 
closure is still unknown and, in many countries, is not subject to national targets, 
unlike the cancer surgery itself. In the EASY trial the median time to closure was 
5 months (bearing in mind that this is a trial population), which is still fairly short 
compared to other countries. A national audit report from the United Kingdom 
reported that within 18 months from surgery, 66% of patients with a stoma 
following anterior resection had undergone stoma reversal118. This has further led 
to a nationwide trial aiming to study the timing of stoma closure, identify causes 
for delay or non-closure and develop guidelines in order to reduce delays in 
closure119.     
In line with the importance of the enhanced recovery after surgery (ERAS) 
program, and the increased use of minimal invasive surgical techniques, early 
closure in selected patients may also in the future be a more common part of the 
surgical treatment of rectal cancer. A more precise follow-up on bowel function, 
using the LARS score in practice, will aid the identification and enable early 
management and treatment of patients with low anterior resection syndrome.
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10 APPENDIX 
 
Questionnaires 
SF-36â 
EORTC QLQ-C30 
EORTC QLQ-CR29 
LARS score 
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 Low Anterior Resection Syndrome Score – LARS Score. English version 1.0  
 
Translated March 2013 by Nick J. Battersby, Department of Colorectal Surgery, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK  
Bowel function questionnaire  
  
The aim of this questionnaire is to assess your bowel function.   
Please tick only one box for each question. It may be difficult to select only 
one answer, as we know that for some patients symptoms vary from day to 
day. We would kindly ask you to choose one answer which best describes 
your daily life. If you have recently had an infection affecting your bowel 
function, please do not take this into account and focus on answering 
questions to reflect your usual daily bowel function.   
  
  
Do you ever have occasions when you cannot control your flatus (wind)?  
□  No, never  
□  Yes, less than once per week  
□  Yes, at least once per week     
Do you ever have any accidental leakage of liquid stool?  
□  No, never  
□  Yes, less than once per week  
□  Yes, at least once per week  
  
How often do you open your bowels?   
□  More than 7 times per day (24 hours) 
□  4-7 times per day (24 hours) 
□  1-3 times per day (24 hours) 
□  Less than once per day (24 hours)    
Do you ever have to open your bowels again within one hour of the last 
bowel opening?  
□  No, never  
□  Yes, less than once per week  
□  Yes, at least once per week     
Do you ever have such a strong urge to open your bowels that you have to 
rush to the toilet?  
□  No, never  
□  Yes, less than once per week  
□  Yes, at least once per week  
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